Publications by authors named "Insa Gathmann"

Claim this Profile
G
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Nikolaus Jahn, Ekaterina Jahn, Maral Saadati, Lars Bullinger, Richard A Larson, Insa Gathmann

Leukemia· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Frank G Rücker, Ling Du, Tamara J Luck, Axel Benner, Julia Krzykalla, Insa Gathmann

Leukemia· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Richard A Larson, Sumithra J Mandrekar, Lucas J Huebner, Ben L Sanford, Kristina Laumann, Insa Gathmann

Leukemia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials.
Mouna Akacha, Janice Branson, Frank Bretz, Bharani Dharan, Paul Gallo, Insa Gathmann

Stat Biopharm Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Ekaterina Panina, Agnes Gambietz, Insa Gathmann

Blood· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
François Guilhot, Timothy P Hughes, Jorge Cortes, Brian J Druker, Michele Baccarani, Insa Gathmann

Haematologica· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
François Guilhot, Brian Druker, Richard A Larson, Insa Gathmann, Charlene So

Haematologica· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Richard A Larson, Brian J Druker, Francois Guilhot, Stephen G O'Brien, Gilles J Riviere, Insa Gathmann

Blood· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.
John Porter, Renzo Galanello, Giuseppe Saglio, Ellis J Neufeld, Elliott Vichinsky, Insa Gathmann

Eur J Haematol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Michael W N Deininger, Jorge Cortes, Ron Paquette, Byung Park, Andreas Hochhaus, Insa Gathmann

Cancer· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Brian J Druker, François Guilhot, Stephen G O'Brien, Insa Gathmann, Hagop Kantarjian

N Engl J Med· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).
Marlene A Dressman, Rachel Malinowski, Lee Anne McLean, Insa Gathmann, Renaud Capdeville

Clin Cancer Res· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Lee Anne McLean, Insa Gathmann, Renaud Capdeville, Mihael H Polymeropoulos, Marlene Dressman

Clin Cancer Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Tim P Hughes, Jaspal Kaeda, Susan Branford, Zbigniew Rudzki, Andreas Hochhaus, Insa Gathmann

N Engl J Med· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Stephen G O'Brien, François Guilhot, Richard A Larson, Insa Gathmann, Michele Baccarani

N Engl J Med· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Oliver G Ottmann, Brian J Druker, Charles L Sawyers, John M Goldman, Jose Reiffers, Insa Gathmann

Blood· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Charles L Sawyers, Andreas Hochhaus, Eric Feldman, John M Goldman, Carole B Miller, Insa Gathmann

Blood· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Moshe Talpaz, Richard T Silver, Brian J Druker, John M Goldman, Carlo Gambacorti-Passerini, Insa Gathmann

Blood· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis